Early access to experimental cancer drugs before approval
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This program provides early access to two experimental cancer drugs, botensilimab and balstilimab, for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious or life-threatening disease.
- You have tried standard treatments and no other satisfactory options are available.
- Your doctor agrees that the potential benefits of this treatment outweigh the risks.
- You are not eligible for any ongoing clinical trial of these drugs, or you cannot access one due to where you live.
- Your treating doctor must request this program on your behalf.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
This program provides access to two investigational drugs, balstilimab and zalifrelimab, for people who have already completed a related clinical trial. It aims to offer continued treatment options for those who may benefit.
This trial offers access to experimental or non-standard cancer treatments for people with advanced solid tumors who have run out of standard options. The goal is to find new ways to treat cancers that are hard to manage.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This trial tests a combination of two immunotherapy drugs to see if they can stop colorectal cancer from returning after standard treatment. It is for people who still have cancer DNA in their blood after surgery and/or chemotherapy, which means they are at high risk of the cancer coming back.
This trial gives people with serious diseases access to a special cell therapy (a treatment made from your own immune cells) when they have no other options. It's a 'compassionate use' program, meaning the drug is available outside of a clinical trial if you meet certain conditions.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.